Metabolic health
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Metabolic health is the state in which five key biomarkers—blood glucose, triglycerides, HDL cholesterol, blood pressure, and waist circumference—all sit within normal ranges without medication, a condition met by only about 12% of American adults and an estimated 20% of Canadians.
What it is
Metabolic health is the state in which five core biomarkers—fasting blood glucose, triglycerides, HDL cholesterol, blood pressure, and waist circumference—all fall within clinically normal ranges without the need for medication, a threshold met by only an estimated 12–20% of adults in high-income countries including Canada. Also called cardiometabolic health or metabolic wellness, the term describes how efficiently the body converts food into energy, regulates blood sugar, manages fat storage, and maintains hormonal balance across tissues. When even one of these five markers falls outside its target range, the pattern is often labelled metabolic syndrome (also called insulin resistance syndrome), a cluster that roughly doubles the risk of cardiovascular disease and raises type 2 diabetes risk fivefold.
In Canada, Diabetes Canada estimates that more than 11 million Canadians live with diabetes or prediabetes, and metabolic syndrome affects approximately 1 in 5 adults—making metabolic health one of the most consequential targets in preventive medicine. Hormones are central to this picture: insulin, estrogen, testosterone, cortisol, thyroid hormones, and leptin all regulate glucose uptake, fat distribution, and inflammatory tone. Disruption to any of these signals can shift multiple biomarkers simultaneously.
Key metabolic health targets (Canadian reference ranges)
| Biomarker | Healthy target | Metabolic syndrome threshold |
|---|---|---|
| Fasting blood glucose | < 5.6 mmol/L | ≥ 5.6 mmol/L |
| Triglycerides | < 1.7 mmol/L | ≥ 1.7 mmol/L |
| HDL cholesterol (women) | ≥ 1.3 mmol/L | < 1.3 mmol/L |
| HDL cholesterol (men) | ≥ 1.0 mmol/L | < 1.0 mmol/L |
| Blood pressure | < 130/85 mmHg | ≥ 130/85 mmHg |
| Waist circumference (women) | < 88 cm | ≥ 88 cm |
| Waist circumference (men) | < 102 cm | ≥ 102 cm |
Three or more of the above thresholds met = metabolic syndrome per the IDF/AHA harmonized criteria.
Causes and mechanism
Metabolic health deteriorates when the body's hormonal signalling network loses its precision. Insulin resistance—where cells respond poorly to insulin's signal to absorb glucose—is the most common entry point. Excess visceral fat amplifies this by releasing pro-inflammatory cytokines (adipokines) that further blunt insulin receptor activity in the liver and muscle.
Sex hormones play a direct role. Estrogen promotes insulin sensitivity, favours subcutaneous over visceral fat storage, and supports favourable lipid profiles. Research from McGill University Health Centre (2024) confirms that estrogen, androgens, and progesterone each regulate cardiometabolic function beyond their reproductive roles. When estrogen declines at perimenopause, visceral fat accumulation accelerates and fasting glucose often rises—even in women who were previously metabolically healthy. Testosterone deficiency in men produces a parallel shift: reduced lean mass, increased central adiposity, and worsening insulin sensitivity.
Cortisol excess (from chronic stress or conditions like Cushing syndrome) raises blood glucose and promotes abdominal fat deposition. Thyroid hormone insufficiency slows basal metabolic rate and raises LDL cholesterol. Leptin resistance—common in obesity—disrupts appetite regulation and energy expenditure. These hormonal axes interact: a 2023 review in Clinical Science (Tao & Cheng) showed that insulin and estrogen signalling pathways converge at multiple intracellular nodes, meaning dysfunction in one system frequently impairs the other.
Symptoms and diagnosis
Poor metabolic health is largely silent in its early stages. When symptoms do appear, they may include fatigue after meals, difficulty losing abdominal weight, brain fog, elevated thirst or urination, and disrupted sleep. None of these are specific enough to diagnose metabolic syndrome on their own.
Diagnosis relies on lab work and physical measurement. In Canada, standard metabolic screening through LifeLabs or Dynacare typically includes a fasting lipid panel, fasting glucose or HbA1c, and a basic metabolic panel. A clinician will also measure waist circumference and blood pressure. Metabolic syndrome is confirmed when three or more of the five criteria in the table above are met. Insulin resistance can be estimated using the HOMA-IR calculation (fasting insulin × fasting glucose ÷ 22.5), though this test is not universally covered under provincial health plans and its clinical cut-offs vary by lab.
Treatment options
Lifestyle modification remains the first-line intervention with the strongest evidence base. A 5–10% reduction in body weight improves all five metabolic markers in most people. Specific approaches with consistent trial support include:
- Dietary pattern changes — Mediterranean-style and low-glycaemic-index diets reduce fasting glucose and triglycerides within 8–12 weeks in randomized trials.
- Aerobic and resistance exercise — 150 minutes per week of moderate aerobic activity, combined with 2 sessions of resistance training, improves insulin sensitivity independent of weight loss.
- Sleep optimization — fewer than 6 hours of sleep per night is independently associated with insulin resistance; addressing sleep apnea can meaningfully improve glucose control.
When hormonal disruption is a contributing factor, targeted hormone therapy may be appropriate. Menopausal hormone therapy (MHT) initiated early in the menopause transition has been shown to attenuate visceral fat gain and reduce new-onset type 2 diabetes risk by approximately 30% in observational data, though randomized evidence on metabolic endpoints specifically remains limited. Testosterone replacement in men with confirmed hypogonadism improves lean mass and insulin sensitivity. Thyroid hormone replacement normalizes lipid profiles in hypothyroidism. Metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors are pharmacological options when lifestyle changes are insufficient; prescribing decisions should involve a physician or nurse practitioner.
Canadian patients can access initial assessments and follow-up through their family physician, an endocrinologist, or virtual care platforms such as Felix, Maple, Cleo, or Phoenix, depending on their province and benefit coverage.
When to see a clinician in Canada
See a clinician if you have a family history of type 2 diabetes or cardiovascular disease, if your waist circumference exceeds the thresholds above, or if routine bloodwork shows any single metabolic marker outside its target range. Canadians over 40 are eligible for periodic health exams that include fasting glucose and lipid screening under most provincial plans. If you are perimenopausal or postmenopausal and noticing rapid changes in weight distribution or energy, ask your clinician to include a full metabolic panel alongside any hormone assessment—these conversations are increasingly supported by SOGC guidance on menopause management.
Limitations and open questions
Research is still emerging on several fronts. The five-marker definition of metabolic syndrome, while widely used, does not capture all relevant dimensions of metabolic health—emerging markers such as fasting insulin, uric acid, and inflammatory proteins (hsCRP, IL-6) may add predictive value but are not yet part of standard Canadian screening protocols. Health Canada has not issued a unified national metabolic health screening guideline that integrates hormonal contributors, leaving clinical practice variable across provinces.
The optimal timing and formulation of hormone therapy for metabolic benefit remains debated. Most positive data on MHT and metabolic outcomes come from observational studies; randomized controlled trials with metabolic endpoints as primary outcomes are limited. The relationship between testosterone therapy and cardiovascular risk in men with borderline-low testosterone is also unresolved. Individual variation in gut microbiome composition, genetic insulin signalling variants, and sleep architecture means that population-level recommendations may not translate uniformly to individual patients.
FAQs
What are the 5 markers of metabolic health?
The five markers used to define metabolic health are fasting blood glucose, triglycerides, HDL cholesterol, blood pressure, and waist circumference. In Canadian clinical practice, the targets are fasting glucose below 5.6 mmol/L, triglycerides below 1.7 mmol/L, HDL above 1.3 mmol/L for women and 1.0 mmol/L for men, blood pressure below 130/85 mmHg, and waist circumference below 88 cm for women and 102 cm for men. Having three or more of these outside their target ranges—with or without medication—meets the criteria for metabolic syndrome.
How do hormones like estrogen and testosterone affect metabolic health?
Estrogen promotes insulin sensitivity, supports favourable lipid profiles, and directs fat storage toward the hips and thighs rather than the abdomen. When estrogen declines at perimenopause, visceral fat accumulation accelerates and fasting glucose often rises. Testosterone in men plays a parallel role: low testosterone is associated with reduced lean muscle mass, increased central adiposity, and worsening insulin sensitivity. A 2024 review from McGill University Health Centre confirmed that sex hormones regulate cardiometabolic function well beyond their reproductive roles.
Can poor metabolic health be reversed?
Yes, metabolic syndrome and its individual components are largely reversible, particularly in earlier stages. A 5–10% reduction in body weight improves all five metabolic markers in most people, and 150 minutes of moderate aerobic exercise per week improves insulin sensitivity independent of weight loss. Dietary changes—especially Mediterranean-style or low-glycaemic-index patterns—can normalize fasting glucose and triglycerides within 8–12 weeks in randomized trials. Reversal is harder once type 2 diabetes or significant cardiovascular disease has developed, which is why early intervention matters.
Is metabolic health testing covered by provincial health plans in Canada?
Basic metabolic screening—fasting glucose, HbA1c, and a fasting lipid panel—is covered under most provincial health plans when ordered by a physician or nurse practitioner, and can be done through LifeLabs or Dynacare. Waist circumference and blood pressure are measured at no cost during a routine physical exam. Fasting insulin and HOMA-IR (used to estimate insulin resistance) are not universally covered and may require an out-of-pocket payment depending on your province and the clinical indication documented by your provider.
How is metabolic health different from metabolic syndrome?
Metabolic health is the positive state—all five biomarkers within normal ranges without medication—while metabolic syndrome is the clinical diagnosis given when three or more of those five markers fall outside their targets. Think of metabolic health as a spectrum: you can have one or two markers slightly off (sometimes called 'metabolically at risk') without meeting the full syndrome criteria. Metabolic syndrome affects approximately 1 in 5 Canadian adults and roughly doubles cardiovascular disease risk while raising type 2 diabetes risk fivefold.
Sources
- Hormonal regulation of metabolism—recent lessons learned from insulin and estrogen
- Metabolic hormones are integral regulators of female reproductive health and function
- Beyond reproduction: unraveling the impact of sex hormones on cardiometabolic health
- Diabetes Canada Clinical Practice Guidelines
- SOGC Menopause and Osteoporosis Guideline
- Metabolic Syndrome — Mayo Clinic